

SECTION	SUBJECT	PAGE						
RESTRICTED USE	Basal insulins (insulin glargine and detemir)	1 of 1						
	Original	<table border="1"> <thead> <tr> <th>YY</th> <th>MM</th> <th>DD</th> </tr> </thead> <tbody> <tr> <td>14</td> <td>09</td> <td>26</td> </tr> </tbody> </table>	YY	MM	DD	14	09	26
YY	MM	DD						
14	09	26						

Coverage for basal insulin products shall be granted provided the following conditions are met:

PROTOCOL 1

- With insulin-dependent diabetes clients that have experienced uncontrolled hypoglycemia, particularly nocturnal or unpredictable, **AND**
- When dose reductions of NPH insulin have not successfully managed uncontrolled hypoglycemia. Relaxed glyceimic targets (or HgB A1c) can be achieved with NPH used in conservative doses to minimize hypoglycemic risk, **AND**
- When a trial of insulin glargine or detemir for a period of fourteen (14) days have been demonstrated to be effective for managing uncontrolled hypoglycemia. Glycemic control values prior to the trial and during the trial must be indicated on the HCD funding request form.

Or

PROTOCOL 2

- When consultation with an Endocrinologist or Internist, results in recommendations for use when patients have not met glyceimic control with other conventional basal insulins.

NOTES:

- Do not mix or dilute with other insulins or solutions.
- Vials should be stored in the refrigerator and not allowed to freeze.
- Vials in use may be kept un-refrigerated for up to 30-42 days (as directed by manufacturer – check product monograph), protected from direct heat & light.